SCHEMBL25367156

SCHEMBL25367156

S=C1NCC(Cc2ccc(Cl)cc2)N1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
REN P00797 5/20 0.35
CTSD P07339 2/20 0.35
CTSE P14091 2/20 0.35
PGC P20142 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CMA1 P23946 1/20 0.35
DBH P09172 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC6A3 Q01959 1/20 0.33
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25365743 0.83 ALDH1A1 (0.36) MEN1KMT2AALDH1A1DBHIDO1
SCHEMBL25366852 0.83 SMN1; SMN2 (0.36) MEN1KMT2AALDH1A1CYP3A4IDO1
SCHEMBL1598073 0.82 MEN1 (0.47) MEN1KMT2AALDH1A1
SCHEMBL25365107 0.81 KMT2A (0.42) KMT2AALDH1A1CMA1DBHCYP3A4
SCHEMBL30528591 0.81 KMT2A (0.42) KMT2AALDH1A1CMA1DBHCYP3A4
SCHEMBL25365104 0.81 KMT2A (0.42) KMT2AALDH1A1CMA1DBHCYP3A4
SCHEMBL25366273 0.79 MAPK1 (0.41) MEN1KMT2AALDH1A1CYP3A4CYP2D6
SCHEMBL25366278 0.79 MAPK1 (0.41) MEN1KMT2AALDH1A1CYP3A4CYP2D6
SCHEMBL25366060 0.73 KMT2A (0.39) MEN1KMT2AALDH1A1CMA1CYP3A4
SCHEMBL25366451 0.71 NPC1 (0.41) MEN1KMT2AALDH1A1DBH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 MEN1 4670/4885KMT2A 4150/4885REN 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.